Zacks Investment Research on MSN6h
FDA Accepts Sanofi's Filing for Multiple Sclerosis Drug Tolebrutinib (Revised)
Sanofi SNY announced that the FDA has accepted its regulatory filing seeking approval for its investigational BTK inhibitor ...
Sanofi Agrees US Autoimmune Drug Deal for Up to $1.9 Billion
Sanofi is buying an immunology drug from Dren Bio, Inc. for up to $1.9 billion, in a deal it said will help it become a ...
Pharmaceutical Technology12h
FDA fast tracks Sanofi’s mRNA vaccine for chlamydia
Sanofi will commence a Phase I/II trial with its vaccine candidate in the next few days to start generating immunogenicity ...
pharmaphorum23h
FDA starts review of Sanofi's MS hope tolebrutinib
The FDA review – which is due to be completed by 28th September – revolves around the results of the HERCULES trial which ...
BioPharma Dive5d
Sanofi wagers $600M on a dual-targeting antibody drug for autoimmune disease
The deal with startup Dren Bio hands Sanofi a so-called myeloid cell engager that would compete with an array of programs ...
Serbian Monitor1d
Serbian scientists sell drug for autoimmune diseases and cancer for $1.9 billion
Sanofi, one of the world’s largest pharmaceutical companies, has acquired the Serbian biopharmaceutical company Dren Bio for ...
Sanofi reports tolebrutinib submission accepted for FDA priority review
The U.S. Food and Drug Administration is evaluating under priority review the regulatory submission of tolebrutinib to treat non-relapsing ...
MedCity News5d
Sanofi Expands Immunology Prospects, Acquiring Novel Bispecific Drug in $600M Deal
Sanofi is adding a new contender, agreeing to pay $600 million for a bispecific drug with an approach that could be first in class. The sum announced Thursday is an upfront payment for Dren Bio ...
Pharmaceutical Technology on MSN5d
Sanofi outlays $1.9bn to purchase Dren Bio’s bispecific antibody
Sanofi’s move for Dren Bio’s clinical asset boosts its immunology-focused strategy of becoming a leader in the field.
EconoTimes6d
Sanofi to Acquire Dren Bio’s Autoimmune Drug DR-0201 in $1.9B Deal
Sanofi (NASDAQ:SNY) has struck a major deal to acquire Dren Bios autoimmune disease treatment, DR-0201, reinforcing its ...
BioSpace5d
Sanofi Commits up to $1.9B for Dren Bio’s Bispecific Antibody for Autoimmune Disease
The deal is the latest in a series of Sanofi investments in its immunology portfolio. According to Sanfoi, DR-0201 can ...
Sanofi: Chlamydia vaccine candidate granted fast track designation by the US FDA
Chlamydia vaccine candidate granted fast track designation by the US FDA Chlamydia infection can contribute to pelvic inflammatory diseases in women, which can lead to pregnancy complications or infer ...